UA97946C2 - Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека - Google Patents

Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека

Info

Publication number
UA97946C2
UA97946C2 UAA200809418A UAA200809418A UA97946C2 UA 97946 C2 UA97946 C2 UA 97946C2 UA A200809418 A UAA200809418 A UA A200809418A UA A200809418 A UAA200809418 A UA A200809418A UA 97946 C2 UA97946 C2 UA 97946C2
Authority
UA
Ukraine
Prior art keywords
monoclonal antibody
specifically binds
extracellular domain
human ilt7
ferm
Prior art date
Application number
UAA200809418A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Юмико КАМОГАВА
Минквон Чо
Наоко Арай
Кои Ишида
Original Assignee
Эс-Би-Ай Биотех Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эс-Би-Ай Биотех Ко., Лтд. filed Critical Эс-Би-Ай Биотех Ко., Лтд.
Publication of UA97946C2 publication Critical patent/UA97946C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
UAA200809418A 2005-12-20 2006-12-20 Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека UA97946C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
PCT/JP2006/325391 WO2007072866A1 (ja) 2005-12-20 2006-12-20 抗ｉｌｔ７抗体

Publications (1)

Publication Number Publication Date
UA97946C2 true UA97946C2 (ru) 2012-04-10

Family

ID=38188642

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200809418A UA97946C2 (ru) 2005-12-20 2006-12-20 Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека

Country Status (29)

Country Link
US (6) US8084585B2 (cg-RX-API-DMAC7.html)
EP (4) EP2532681B1 (cg-RX-API-DMAC7.html)
JP (2) JP5020828B2 (cg-RX-API-DMAC7.html)
KR (3) KR101585532B1 (cg-RX-API-DMAC7.html)
CN (5) CN105111311B (cg-RX-API-DMAC7.html)
AU (1) AU2006328470B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0620141B1 (cg-RX-API-DMAC7.html)
CA (2) CA2634116C (cg-RX-API-DMAC7.html)
CY (3) CY1114227T1 (cg-RX-API-DMAC7.html)
DK (3) DK2913343T3 (cg-RX-API-DMAC7.html)
ES (3) ES2699428T3 (cg-RX-API-DMAC7.html)
HK (1) HK1218126A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20130494T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039865T2 (cg-RX-API-DMAC7.html)
IL (1) IL192266A (cg-RX-API-DMAC7.html)
LT (1) LT2913343T (cg-RX-API-DMAC7.html)
ME (1) ME02111B (cg-RX-API-DMAC7.html)
MX (1) MX2008007682A (cg-RX-API-DMAC7.html)
NZ (3) NZ569910A (cg-RX-API-DMAC7.html)
PL (3) PL1964852T3 (cg-RX-API-DMAC7.html)
PT (3) PT2913343T (cg-RX-API-DMAC7.html)
RS (2) RS53752B1 (cg-RX-API-DMAC7.html)
RU (2) RU2456298C2 (cg-RX-API-DMAC7.html)
SG (2) SG170749A1 (cg-RX-API-DMAC7.html)
SI (3) SI2532681T1 (cg-RX-API-DMAC7.html)
TR (1) TR201816574T4 (cg-RX-API-DMAC7.html)
UA (1) UA97946C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007072866A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200805850B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP2563393B1 (en) 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
CA2831426C (en) 2011-04-01 2023-02-21 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
PL2828284T3 (pl) 2012-03-20 2019-11-29 Biogen Ma Inc Przeciwciała neutralizujące wirus jc
EP2890715B1 (en) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
CN104755498B (zh) 2012-08-31 2019-06-18 伊缪诺金公司 用于检测叶酸受体1的诊断测定和试剂盒
US9637547B2 (en) 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3270965B1 (en) * 2015-03-18 2020-05-06 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
SI3313884T1 (sl) * 2015-06-29 2021-04-30 Immunogen, Inc. Protitelesa proti CD123 ter njihovi konjugati in derivati
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2018006249A (es) * 2015-11-19 2018-11-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-emr2 y metodos de uso.
CN109069211B (zh) 2016-01-26 2022-04-29 网络牙科(美国)公司 自动牙科治疗系统
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP3426298A4 (en) * 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF
EA201892225A1 (ru) * 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
EP3675898A4 (en) 2017-08-30 2021-09-01 Phanes Therapeutics, Inc. ANTI-LAG-3 ANTIBODIES AND THEIR USES
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
CA3082409A1 (en) * 2017-11-17 2019-05-23 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
KR20200103751A (ko) * 2017-12-20 2020-09-02 라디뮨 테라퓨틱스 인코포레이티드 센트린-1에 대한 항체, 이의 제조 방법, 및 용도
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
US20210251721A1 (en) 2018-05-10 2021-08-19 Cyberdontics (Usa), Inc. Automated dental drill
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
EP4013510A1 (en) 2019-08-12 2022-06-22 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
EP4069288A4 (en) * 2019-12-06 2024-01-17 Viela Bio, Inc. TREATMENT METHODS USING ILT7 BINDING PROTEINS
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
KR20250042166A (ko) 2022-07-27 2025-03-26 비엘라 바이오, 인크. 면역글로불린-유사 전사체 7(ilt7) 결합 단백질을 포함하는 제형
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
KR20250160358A (ko) * 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
EP2332579A3 (en) * 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US7485713B2 (en) * 2001-10-13 2009-02-03 Asterion Limited Polypeptides comprising growth hormone receptor extracellular domain and glycosylphosphatidylinositol
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
HK1218126A1 (zh) 2017-02-03
ES2699428T3 (es) 2019-02-11
EP2532681A1 (en) 2012-12-12
ME02111B (me) 2015-10-20
EP2913343A1 (en) 2015-09-02
US20160130343A1 (en) 2016-05-12
HK1124347A1 (en) 2009-07-10
US8084585B2 (en) 2011-12-27
WO2007072866A1 (ja) 2007-06-28
DK2913343T3 (en) 2018-11-26
JP5020828B2 (ja) 2012-09-05
JP5420688B2 (ja) 2014-02-19
ES2416716T3 (es) 2013-08-02
CN103360492A (zh) 2013-10-23
US20120135003A1 (en) 2012-05-31
AU2006328470A2 (en) 2008-10-09
CA2994756A1 (en) 2007-06-28
PL2913343T3 (pl) 2019-03-29
PL2532681T3 (pl) 2015-03-31
RU2456298C2 (ru) 2012-07-20
JPWO2007072866A1 (ja) 2009-06-04
KR101526934B1 (ko) 2015-06-26
SI2913343T1 (sl) 2019-01-31
CA2634116C (en) 2018-03-27
RS52860B (sr) 2013-12-31
KR20150031485A (ko) 2015-03-24
BRPI0620141A2 (pt) 2011-11-01
ZA200805850B (en) 2009-04-29
RU2008129715A (ru) 2010-01-27
BRPI0620141B1 (pt) 2024-04-30
CN110776566B (zh) 2025-07-15
NZ616992A (en) 2015-07-31
DK1964852T3 (da) 2013-07-08
US20170204179A1 (en) 2017-07-20
RU2012112046A (ru) 2013-10-10
PT1964852E (pt) 2013-07-10
HRP20141226T1 (hr) 2015-02-27
IL192266A (en) 2014-09-30
EP1964852B1 (en) 2013-04-17
SI2532681T1 (sl) 2015-03-31
PL1964852T3 (pl) 2013-09-30
JP2012143232A (ja) 2012-08-02
AU2006328470A1 (en) 2007-06-28
CN110776566A (zh) 2020-02-11
HUE039865T2 (hu) 2019-02-28
RS53752B1 (sr) 2015-06-30
KR101585532B1 (ko) 2016-01-14
EP1964852A1 (en) 2008-09-03
EP2532681B1 (en) 2014-10-01
HRP20130494T1 (en) 2013-08-31
MX2008007682A (es) 2008-10-23
LT2913343T (lt) 2018-11-26
CA2994756C (en) 2020-10-27
EP3441403A1 (en) 2019-02-13
CA2634116A1 (en) 2007-06-28
US8470992B2 (en) 2013-06-25
RU2599450C2 (ru) 2016-10-10
SG10201602095PA (en) 2016-05-30
CY1116031T1 (el) 2017-01-25
EP1964852A4 (en) 2010-02-24
DK2532681T3 (en) 2015-01-05
US20200339682A1 (en) 2020-10-29
CN105111311B (zh) 2019-10-18
CY1114227T1 (el) 2016-08-31
US20090280128A1 (en) 2009-11-12
US20130259872A1 (en) 2013-10-03
KR101624587B1 (ko) 2016-05-26
SG170749A1 (en) 2011-05-30
CN101379089B (zh) 2013-08-07
PT2913343T (pt) 2018-11-21
CN105111311A (zh) 2015-12-02
ES2526079T3 (es) 2015-01-05
CY1121294T1 (el) 2020-05-29
IL192266A0 (en) 2008-12-29
SI1964852T1 (sl) 2013-09-30
HK1214603A1 (en) 2016-07-29
NZ599683A (en) 2013-11-29
AU2006328470B2 (en) 2012-08-16
KR20080090430A (ko) 2008-10-08
KR20140053232A (ko) 2014-05-07
PT2532681E (pt) 2014-12-23
HK1179638A1 (en) 2013-10-04
EP2913343B1 (en) 2018-08-08
CN120718150A (zh) 2025-09-30
CN101379089A (zh) 2009-03-04
TR201816574T4 (tr) 2018-11-21
NZ569910A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
DE602006013029D1 (de) Anti-egfr-antikörper
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
MY157173A (en) Modified humanised anti-interleukin-18
UA92504C2 (en) Anti-myostatin monoclonal antibody
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
TW200626171A (en) Fixed dosing of HER antibodies
NZ588674A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
NZ595863A (en) Antibodies to egfl7 and methods for their use
WO2011158122A3 (en) Anti-human equilibrative nucleoside transporter 1 (hent1) antibodies and methods of use thereof
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13